Leerink Partners analyst David Risinger maintained a Buy rating on Eli Lilly & Co (LLY – Research Report) on January 24 and set a price ...

Lots of people are on cheaper compounded weight-loss drugs that mimic brands like Ozempic, Wegovy, and Zepbound. They're ...

For its most recently reported quarter (Q3 of 2024), Hims & Hers generated $401.6 million in revenue. That resulted in a free ...

If your weight loss goals have taken a backward step, this simple device might be all you need to get back on track and shed ...

But, no matter what direction the general market takes, some stocks could stand out, potentially in 2025, and most ...

Vertex's lineup will look transformed in five years, and the company should continue performing well beyond that time. It's ...

It's the start of a new year, and that makes now the perfect time to load up on stocks that could boost your portfolio in ...

In clinical trials, tirzepatide (the active ingredient in both Mounjaro and ... profits (based on analyst estimates), Eli ...

Lilly makes tirzepatide, sold under the name Zepbound for weight loss and Mounjaro for type 2 diabetes. These products have quickly become blockbusters, bringing in billions of dollars in revenue.

The yearlong downtrend in obesity drug supplier Novo Nordisk (NVO) is potentially over. Last Friday, Jan. 25, NVO stock gained 8.47% to close at $87.97. The company posted the results of its obesity ...